Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12294973 | 0.83 | ALOX5 (0.37) | ALOX5ALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL2038522 | 0.78 | ALDH1A1 (0.36) | ALOX5ALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL684232 | 0.77 | — | — | |
| SCHEMBL11970362 | 0.75 | ALOX5 (0.34) | ALOX5ALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL14152670 | 0.75 | — | — | |
| SCHEMBL9372859 | 0.75 | — | — | |
| SCHEMBL8682749 | 0.74 | MEN1 (0.42) | ALOX5ALDH1A1TSHRNOS1HSD17B10 | |
| Hydrochloric Acid SCHEMBL14889613 | 0.73 | ALDH1A1 (0.44) | ALOX5ALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL8682794 | 0.73 | ALDH1A1 (0.40) | ALOX5ALDH1A1TSHRNOS1HSD17B10 | |
| SCHEMBL20921140 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4195928-B1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII | BASF SE (DE) | 2025-06-18 | — | — | EP | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20230357152-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII | BASF SE (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-4195928-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII | BASF SE (DE) | 2023-06-21 | — | — | EP | disclosed |
| CN-116056576-A | Use of strobilurin type compounds for combating phytopathogenic fungi containing F129L amino acid substitutions conferring tolerance to Qo inhibitor VIII in mitochondrial cytochrome b proteins | 巴斯夫欧洲公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106289-A1 | NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-04-07 | — | — | US | disclosed |
| EP-3970494-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII | BASF SE (DE) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022033906-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII | BASF SE (DE) | 2022-02-17 | — | — | WO | disclosed |
| EP-3883646-A1 | NLRP3 INHIBITORS | Inflazome Limited (IE) | 2021-09-29 | — | — | EP | disclosed |
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | NOVARTIS AG (CH) | 2007-09-27 | — | — | US | disclosed |
| EP-1749005-A1 | TETRAHYDRO-IMIDAZO ¬1,5-A| PYRIDIN DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| EP-1605946-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005118581-A1 | TETRAHYDRO-IMIDAZO [1,5-A] PYRIDIN DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004087699-A2 | THIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1177175-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-02-06 | — | — | EP | disclosed |
| US-6200993-B1 | ASTHMA; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-03-13 | — | — | US | disclosed |
| WO-2000068198-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-16 | — | — | WO | disclosed |
| WO-1997046543-A1 | ACETYL DERIVATIVES OF THIAZOLES AND ANALOGUES | THE UNIVERSITY OF WOLLONGONG (AU) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | ALOX5 353/4885ALDH1A1 1078/4885TSHR 2925/4885 |
| US-20070225232-A1 | Tetrahydro-Imidazo [1,5-A] Pyridyin Derivatives as Aldosterone Synthase Inhibitors | CYP21A2, CYP11B1, REN | ALOX5 415/4885ALDH1A1 430/4885TSHR 878/4885 |
| US-20050004150-A1 | For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders | TSLP, JAK1, SERPINB1 | ALOX5 984/4885ALDH1A1 2984/4885TSHR 4496/4885 |
| US-20220106289-A1 | NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ALOX5 1423/4885ALDH1A1 1930/4885TSHR 4765/4885 |
| US-20230357152-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS VIII | COX5B, COX6B1, SQOR | ALOX5 3549/4885ALDH1A1 4157/4885TSHR 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.